Evidence map›Paper›PMID 39040198›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Low coverage whole genome sequencing of low-grade dysplasia strongly predicts colorectal cancer risk in ulcerative colitis.

Ibrahim Al Bakir, Kit Curtius, George D Cresswell, Heather E Grant, Nadia Nasreddin, Kane Smith, Salpie Nowinski, Qingli Guo, Hayley L Belnoue-Davis, Jennifer Fisher and 15 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Ibrahim Al BakirBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Kit CurtiusBarts Cancer Institute, Queen Mary University of London, United Kingdom.ORCID 0000-0002-2678-0960
George D CresswellCentre for Evolution and Cancer, Institute of Cancer Research, London, United Kingdom.
Heather E GrantCentre for Evolution and Cancer, Institute of Cancer Research, London, United Kingdom.
Nadia NasreddinWellcome Centre for Human Genetics, Oxford, United Kingdom.
Kane SmithBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Salpie NowinskiBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Qingli GuoBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Hayley L Belnoue-DavisWellcome Centre for Human Genetics, Oxford, United Kingdom.
Jennifer FisherInflammatory Bowel Disease Unit, St. Mark's Hospital, Harrow, United Kingdom.
Theo ClarkeBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Christopher KimberleyBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Maximilian MossnerBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Philip D DunneQueen's University Belfast, Northern Ireland, United Kingdom.
Maurice B LoughreyQueen's University Belfast, Northern Ireland, United Kingdom.
Ally SpeightNewcastle NHS Foundation Trust, Newcastle, United Kingdom.
James E EastNuffield Department of Medicine, University of Oxford, United Kingdom.
Nicholas A WrightBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Manuel Rodriguez-JustoDepartment of Pathology, University College London Hospital NHS Trust, London, UK.
Marnix JansenDepartment of Pathology, University College London Hospital NHS Trust, London, UK.
Morgan MoorghenInflammatory Bowel Disease Unit, St. Mark's Hospital, Harrow, United Kingdom.
Ann-Marie BakerBarts Cancer Institute, Queen Mary University of London, United Kingdom.
Simon J LeedhamWellcome Centre for Human Genetics, Oxford, United Kingdom.
Ailsa L HartInflammatory Bowel Disease Unit, St. Mark's Hospital, Harrow, United Kingdom.
Trevor A GrahamBarts Cancer Institute, Queen Mary University of London, United Kingdom.ORCID 0000-0001-9582-1597

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Multiscale modeling of spatiotemporal evolution in Barrett's esophagusR01CA270235 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kathleen M. Curtius · 2023 to 2026
$2.3M
Mathematical Optimization of Surveillance Ages to Intercept colitis-associated Colorectal cancer (MOSAIC)I01BX005958 · VA · VA SAN DIEGO HEALTHCARE SYSTEM · PI CURTIUS, KATHLEEN M. · 2023 to 2025
–
BLRD VA I01 BX005958Cancer Research UK 25901NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA270235NIDDK NIH HHS P30 DK120515
6 · The paper itself

Abstract

Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC), and this risk increases dramatically in those who develop low-grade dysplasia (LGD). However, there is currently no accurate way to risk-stratify patients with LGD, leading to both over- and under-treatment of cancer risk. Here we show that the burden of somatic copy number alterations (CNAs) within resected LGD lesions strongly predicts future cancer development. We performed a retrospective multi-centre validated case-control study of n=122 patients (40 progressors, 82 non-progressors, 270 LGD regions). Low coverage whole genome sequencing revealed CNA burden was significantly higher in progressors than non-progressors (p=2×10

Identifiers

PMID39040198
PMCPMC11261962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.